ERBB2 and breast carcinoma: While it is too early to know its impact on brain recurrence in HER2+ve breast cancer patients, the I-SPY2 trial (NCT01042379) evaluating neratinib’s efficacy in the neoadjuvant setting has reported encouraging observations, with an estimated rate of pathological complete response superior to that of the trastuzumab-containing control arm (56% versus 33%, respectively) [72].